Novel food regulations coming into force this year do not apply to Northern Ireland, where CBD companies will have to continue to follow EU law.
With just weeks to go until the deadline for novel food applications in the UK, CBD firms in Northern Ireland have been dealt a “significant blow” as it becomes clear they no longer fall under Food Standards Authority (FSA) regulations, following Brexit.
Believed to have gone unnoticed by many in the industry, the FSA website now includes a note stating that EU law continues to apply to Northern Ireland after the Brexit transition period, as set out in the “Northern Ireland Protocol”.
This means any company seeking authorisation for a CBD product to be placed on the market will have to follow EU rules.
London-based cannabis consultancy firm, The Canna Consultants, who highlighted the position on its website on Wednesday 13 January, described it as a “shock” and “significant body-blow” to businesses in Northern Ireland.
With the UK deadline for novel food applications looming on 31 March, 2021 it is likely that many companies will have already invested in the application process, believing they could remain on the market after this date.
Instead, their products will now be deemed unlawful, until fully authorised by the European Commission (EC) along with the rest of the EU.
Speaking to Cannabis Health, Stephen Oliver, co-founder of The Canna Consultants, said: “Imagine being a Northern Ireland CBD company, which has invested considerable time and money into the compilation of a Novel food dossier having acted upon the FSA announcement of February 2020, in the belief that by achieving validation by the 31 March this year they could remain on the market.
“Now they find that they cannot and are bound, despite being within the UK, by the Commission’s stance that no CBD products can be sold until after authorisation – that could be years.
“The Regulator may say that the products were on the market unlawfully anyway but by creating the amnesty, encouraged people to make commercial decisions who may have chosen to leave the industry or invest towards compliance.”
The protocol could also have a much wider impact on CBD brands elsewhere in the UK, which it is thought, will no longer be able to sell their validated products in Northern Ireland after March 2021.
Oliver continued: “Other issues concern Northern Irish sellers of UK validated CBD products after March 31 – one assumes they will no longer be able to, unless a further provision is made.
“Can a UK company sell in the UK when validated? Yes, but we now see that this will not apply to the whole of the UK in respect of Ireland.”
He added: “Clearly Scotland has its own regulator, but this is not a matter of different regulators setting different paths, rather a direct consequence of our departure from the EU.”
The European CBD industry has been shrouded in uncertainty following a preliminary conclusion issued by the EC last year suggesting CBD should be classified as a narcotic drug rather than a novel food.
It is hoped a European Court of Justice (CJEU) ruling in November that CBD could not be considered a narcotic, will result in a removal of the ban on the advancement of novel food assessments.
Full guidance on novel food regulations from the FSA can be found here
- Malta gives green light to three new cannabis clubs
- European Commission must address ‘inequality’ in access to medicinal cannabis across EU
- 1 in 8 older US adults now use cannabis products, finds study
- 3 main contributors to the entourage effect for cannabis consumers to consider
- Medical cannabis doesn’t impair cognitive function – study
- Ukraine’s medical cannabis legalisation delayed by opponents
- News4 months ago
NHS approves major clinical trial on cannabis medicines and chronic pain
- News6 months ago
UK patient secures first NHS reimbursement for cannabis flowers
- Advocacy6 months ago
Inside a UK cannabis club: changing lives, tackling stigma, building community
- News4 months ago
UK research finds GP support for cannabis as an alternative to opioids for chronic pain
- Industry4 months ago
‘Landmark’ ruling gives hope for UK CBD flower businesses
- Industry6 months ago
New report calls for overhaul of ‘discriminatory’ UK cannabis driving laws
- News4 months ago
Malta: Advocates emphasise positive effects of cannabis reform amid ‘normalisation’ concerns
- Science4 months ago
Five new cannabis studies – ALS, epilepsy, Parkinson’s, chronic pain and blood pressure